Physician profile
Christopher S Nicholson
NPI 1093888745
$4,495.71
in general payments reported to CMS, 2019-2025
38 companies · $797 in 2025
The $797 reported for 2025 was more than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $986 · 2020: $418 · 2021: $234 · 2022: $702 · 2023: $739 · 2024: $620 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $467.44 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $371.35 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $355.94 | 2019-2023 | |
| Pfizer INC. | $331.29 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $321.33 | 2019-2022 | |
| Amgen INC. | $314.87 | 2019-2024 | Repatha |
| Boston Scientific Corporation | $255.75 | 2023-2025 | Watchman Flx, Bodyguardian, Cds - Mct/Cem Monitoring |
| E.R. Squibb & Sons, L.L.C. | $205.89 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $185.99 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $149.79 | 2021-2025 | Verquvo |
| Baxter Healthcare | $131.41 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.38 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $125.10 | 2020-2025 | Farxiga, Wainua |
| Impulse Dynamics (USA) INC. | $111.88 | 2022-2024 | Optimizer, Optimizer |
| Novo Nordisk INC | $88.21 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.